PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer

[1] Perou CM(2000)Molecular portraits of human breast tumours Nature 406 747-752

[2] Sørlie T(2001)Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869-10874

[3] Eisen MB(2013)Estimates of global cancer prevalence for 27 sites in the adult population in 2008 Int J Cancer 132 1133-1145

[4] Van De Rijn M(2014)Clinical characteristics and prognostic analysis of triple-negative breast cancer patients Mol Clin Oncol. 2 245-251

[5] Jeffrey SS(2018)Recent advances in the treatment of breast cancer Front Oncol 121 2750-2767

[6] Rees CA(2011)Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest. 19 5533-5540

[7] Pollack JR(2013)Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes Clin Cancer Res 46 796-804

[8] Ross DT(2007)Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies Genes Chromosomes Cancer 6 199-208

[9] Johnsen H(1997)Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor Immunity 66 10639-10642

[10] Akslen LA(2006)A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer Cancer Res 9 226-135

[1] Perou CM(2000)Molecular portraits of human breast tumours Nature 406 747-752

[2] Sørlie T(2001)Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869-10874

[3] Eisen MB(2013)Estimates of global cancer prevalence for 27 sites in the adult population in 2008 Int J Cancer 132 1133-1145

[4] Van De Rijn M(2014)Clinical characteristics and prognostic analysis of triple-negative breast cancer patients Mol Clin Oncol. 2 245-251

[5] Jeffrey SS(2018)Recent advances in the treatment of breast cancer Front Oncol 121 2750-2767

[6] Rees CA(2011)Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest. 19 5533-5540

[7] Pollack JR(2013)Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes Clin Cancer Res 46 796-804

[8] Ross DT(2007)Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies Genes Chromosomes Cancer 6 199-208

[9] Johnsen H(1997)Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor Immunity 66 10639-10642

[10] Akslen LA(2006)A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer Cancer Res 9 226-135